Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck

Launched by SUN YAT-SEN UNIVERSITY · Feb 1, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a combination of three cancer-fighting medications—paclitaxel (albumin bound), bleomycin, and either cisplatin or carboplatin—specifically for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The goal is to find out how safe these medications are and how effective they are in treating this type of cancer that has either come back or spread to other parts of the body.

To participate, patients need to be at least 18 years old and have a confirmed diagnosis of squamous cell carcinoma of the head and neck, which is at an advanced stage (stage IVc) or has returned after previous treatments. It's important that they do not have any other cancers and that their major organs are functioning well. Participants can expect to receive the study medications and will be closely monitored for any side effects and the effectiveness of the treatment. Additionally, pregnant or breastfeeding women, as well as those who have been involved in another clinical trial recently, are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • biopsy proved squamous cell carcinoma of the head and neck;
• • stage IVc according to Union for International Cancer Control (UICC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
• • 18 years or older; without other malignancy;
• • proper functioning of the major organs.
• Exclusion Criteria:
• • allergic to paclitaxel (albumin bound) or bleomycin or cisplatin or carboplatin ;
• • female within gestation period or lactation;
• • patients received drug of other clinical trial within 3 months